Significant improvement in survival of patients presenting with metastatic colon cancer in the south of The Netherlands from 1990 to 2004

Meulenbeld, Hielke J.; Steenbergen, L.N. van; Janssen‐Heijnen, M.L.G.; Lemmens, Valery; Creemers, Geert-Jan

doi:10.1093/annonc/mdn176

Cited by 43 publications

(28 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our finding of more patients receiving active treatment is consistent with other reports of an increasing use of new agents 10,11 in routine practice. Similarly, separate studies have reported survival changes over time, 12,13 which are of similar magnitude to what we observed. In the absence of comprehensive treatment data in these previous studies, the survival gains were mostly attributed to increased chemotherapy use, with stage migration and earlier diagnosis also thought to be important factors.…”

Section: Discussionsupporting

confidence: 91%

Translation of clinical trial outcomes to metastatic colorectal cancer patients in community practice

Lok

Wong

Kosmider

et al. 2014

Asia-Pac J Clin Oncol

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 91%

Translation of clinical trial outcomes to metastatic colorectal cancer patients in community practice

Lok

Wong

Kosmider

et al. 2014

Asia-Pac J Clin Oncol

View full text Add to dashboard Cite

show abstract

“…Advances in surgical and oncological treatment over the past decades have improved prognosis for stage IV colorectal cancer patients [4,19]. In addition, a better understanding of the underlying tumor biology and the identification of prognostic factors highlighted that stage IV colorectal cancer patients are an inhomogeneous group and treatment must be individualized [6,20].…”

Section: Discussionmentioning

confidence: 99%

“…Before the use of chemotherapy, initial survival of stage IV colorectal cancer patients with supportive care was six months [4,19]. With the successive introduction of chemotherapeutic agents over the past two decades, median survival has been increased to 14-16 months.…”

Section: Discussionmentioning

confidence: 99%

Prognostic factors and survival improvements in stage IV colorectal cancer*

et al. 2011

View full text Add to dashboard Cite

Background: The aim of the study was to evaluate prognostic factors and survival improvements in stage IV colorectal cancer patients who had all undergone resection of their primary tumor.Methods: Between 1982 and 2006, 639 consecutive patients with UICC stage IV colorectal cancer underwent tumor resection followed by chemotherapy. Clinical, surgical, histopathological, and follow-up data were investigated and correlated with survival.Results: Total R0 status was achieved in 101 patients (16%), and 128 patients (20%) underwent multivisceral resection. Median cause-specific survival for total R0 resected patients was 41 (95% CI: 32-50) months. The median cause-specific survival increased continuously from 10 (95% CI: 8-12) months for patients treated in the first years to 23 (95% CI: 19-27) months for those treated in the last 5 years of the study period. Multivariable analysis identified patients' age, pN, cM1a/b, R status, and the date of resection of the primary tumor as independent prognostic factors.Conclusions: Prognosis of stage IV colorectal cancer improved continuously in the last decades. Despite the ongoing discussion if the primary tumors should be resected in stage IV disease, prognostic factors can help to select M1 patients with potential long-term survival, who should undergo resection of the primary tumors and metastases followed by chemotherapy.

show abstract

“…14,21 While survival of patients with metastases confined to the liver was equal to that of peritoneal carcinomatosis in 1995-2001, populationbased survival of these patients rose considerably from 8 to 12 months in the most recent period, thanks to the introduction of more efficient chemotherapeutics. 30 Patients with peritoneal carcinomatosis do not seem to benefit at population level from the availability of the new treatment arsenal.…”

Section: Epidemiologymentioning

confidence: 99%

Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: A population‐based study

Lemmens

Klaver

Verwaal

et al. 2010

Intl Journal of Cancer

297

208

View full text Add to dashboard Cite

The aim of our study was to provide population‐based data on incidence and prognosis of synchronous peritoneal carcinomatosis and to evaluate predictors for its development. Diagnosed in 1995–2008, 18,738 cases of primary colorectal cancer were included. Predictors of peritoneal carcinomatosis were analysed by multivariable logistic regression analysis. Median survival in months was calculated by site of metastasis. In the study period, 904 patients were diagnosed with synchronous peritoneal carcinomatosis (4.8% of total, constituting 24% of patients presenting with M1 disease). The risk of peritoneal carcinomatosis was increased in case of advanced T stage [T4 vs. T1,2: odds ratio (OR) 4.7, confidence limits 4.0–5.6), advanced N stage [N0 vs. N1,2: OR 0.2 (0.1–0.2)], poor differentiation grade [OR 2.1 (1.8–2.5)], younger age [<60 years vs. 70–79 years: OR 1.4 (1.1–1.7)], mucinous adenocarcinoma [OR 2.0 (1.6–2.4)] and right‐sided localisation of primary tumour [left vs. right: OR 0.6 (0.5–0.7)]. Median survival of patients with peritoneum as single site of metastasis remained dismal [1995–2001: 7 (6–9) months; 2002–2008: 8 (6–11) months], contrasting the improvement among patients with liver metastases [1995–2001: 8 (7–9) months; 2002–2008: 12 (11–14) months]. To conclude, synchronous peritoneal metastases from colorectal cancer are more frequent among younger patients and among patients with advanced T stage, mucinous adenocarcinoma, right‐sided tumours and tumours that are poorly differentiated. The prognosis of synchronous peritoneal carcinomatosis remains poor with a median survival of 8 months and even worse if concomitant metastases in other organs are present.

show abstract

Significant improvement in survival of patients presenting with metastatic colon cancer in the south of The Netherlands from 1990 to 2004

Abstract: Palliative chemotherapy significantly improved OS in unselected patients with metastatic colon cancer.

Cited by 43 publications

References 20 publications

Translation of clinical trial outcomes to metastatic colorectal cancer patients in community practice

Translation of clinical trial outcomes to metastatic colorectal cancer patients in community practice

Prognostic factors and survival improvements in stage IV colorectal cancer*

Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: A population‐based study

Contact Info

Product

Resources

About